Ubs Asset Management Americas Inc Tricida, Inc. Transaction History

Ubs Asset Management Americas Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	BUY	$7.31 - $11.85 $208,335 - $337,725	28,500 New	28,500 $275,000
Q2 2021 Aug 16, 2021	SELL	$3.95 - $5.41 $120,475 - $165,005	-30,500 Closed	0 $0
Q3 2020 Nov 13, 2020	BUY	$8.56 - $26.93 $91,669 - $288,393	10,709 Added 54.11%	30,500 $276,000
Q2 2020 Aug 14, 2020	BUY	$21.21 - $31.55 $419,767 - $624,406	19,791 New	19,791 $543,000
Q1 2020 May 15, 2020	SELL	$18.43 - $38.04 $103,208 - $213,024	-5,600 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$29.6 - $43.71 $165,760 - $244,776	5,600 New	5,600 $211,000

30K

124K

46.5K

Ticker TCDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,668,900
Market Cap $557K
Description
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company ...

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

Stay updated on Ubs Asset Management Americas Inc with notifications on news.